ER vs. IR [Design Issues]

posted by Dr_Dan  – 2019-12-19 09:01 (486 d 12:06 ago) – Posting: # 21004
Views: 2,018

Hi Helmut
your statement only holds true in your example with different strengths. If you have only one or the highest IR strength then my statement applies. The once daily (or 8 h) dosing of the ER formulation does not have to mimicry the performance of the multiple dosing of the IR formulation if you can show that there is a well-defined therapeutic window in terms of safety and efficacy and the rate of input is known not to influence the safety and efficacy profile or the risk for tolerance development.

Kind regards and have a nice day

Complete thread:

 Admin contact
21,419 posts in 4,475 threads, 1,508 registered users;
online 14 (0 registered, 14 guests [including 3 identified bots]).
Forum time: Sunday 22:07 CEST (Europe/Vienna)

Nothing fails like success because you do not learn anything from it.
The only thing we ever learn from is failure.
Success only confirms our superstitions.    Kenneth E. Boulding

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz